Development of the ClinESSDAI: A clinical score without biological domain. A tool for biological studies

Annals of the Rheumatic Diseases

Volumn 75, Issue 11, 2016, Pages 1945-1950

  Seror, Raphaèle ^a   Meiners, Petra ^b   Baron, Gabriel ^c   Bootsma, Hendrika ^b   Bowman, Simon J ^d   Vitali, Claudio ^e   Gottenberg, Jacques Eric ^f   Theander, Elke ^g   Tzioufas, Athanasios ^h   De Vita, Salvatore ⁱ   Ramos Casals, Manel ^j   Dörner, Thomas ^k   Quartuccio, Luca ⁱ   Ravaud, Philippe ^c   Mariette, Xavier ^a  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^e Instituto San Giuseppe   (Italy)

^f INSERM   (France)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

ⁱ UNIVERSITY OF UDINE   (Italy)

^j HOSPITAL CLÍNIC   (Spain)

^k CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

more..

Author keywords

Disease Activity; Outcomes research; Sj gren's Syndrome

Indexed keywords

ADULT; ARTICLE; CLINICAL EUROPEAN LEAGUE AGAINST RHEUMATISM SJOGREN SYNDROME DISEASE ACTIVITY INDEX; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; HUMAN; MAJOR CLINICAL STUDY; MUSCULOSKELETAL DISEASE ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; RELIABILITY; SJOEGREN SYNDROME; FEMALE; MALE; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME; VALIDATION STUDY;

FEMALE; HUMANS; MALE; PSYCHOMETRICS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; SJOGREN'S SYNDROME;

EID: 84962168848     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208504     Document Type: Article

References (34)

1. Seror R, Ravaud P, Bowman SJ, et al. EULAR Sjogren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-9
2. Seror R, Ravaud P, Mariette X, et al. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis 2011;70:968-72
3. Seror R, Theander E, Brun JG, et al. Validation of EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient indexes (ESSPRI). Ann Rheum Dis 2015;74:859-66
4. Seror R, Mariette X, Bowman S, et al. Accurate detection of changes in disease activity in primary Sjogren's syndrome by the European league against Rheumatism Sjogren's syndrome disease activity index. Arthritis Care Res (Hoboken) 2010;62:551-8
5. Seror R, Bootsma H, Saraux A, et al. Defining disease activity states and clinically meaningful improvement in primary Sjogren's syndrome with EULAR primary Sjogren's syndrome disease activity (ESSDAI) and patient-reported indexes (ESSPRI) Ann Rheum Dis 2016;75:382-9
6. Gottenberg JE, Seror R, Miceli-Richard C, et al. Serum levels of beta2-microglobulin and free light chains of immunoglobulins are associated with systemic disease activity in primary Sjogren's syndrome. Data at enrollment in the prospective ASSESS cohort. PLoS ONE 2013;8:e59868
7. Brito-Zeron P, Kostov B, Solans R, et al. Systemic activity and mortality in primary Sjogren syndrome: predicting survival using the EULAR-SS Disease Activity Index (ESSDAI) in 1045 patients. Ann Rheum Dis 2016;75:348-55
8. Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sjogren's syndrome: A revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 2002;61:554-8. http://dx.org/10.1136/ard.61.6.554
9. Meiners P.M., Arends S., Brouwer E., et al. Responsiveness of Disease Activity Indices ESSPRI and ESSDAI in Patients with Primary Sjogren's Syndrome Treated with Rituximab. Ann Rheum Dis, 2012, 71 1297-302
10. Mariette X, Seror R, Quartuccio L, et al. Efficacy and safety of belimumab in primary Sjogren's syndrome: results of the BELISS open-label phase II study. Ann Rheum Dis 2015;74:526-31
11. Yohai VJ. High breakdown-point and high efficiency robust estimates for regression Ann Statist 1987;15:642-56
12. Rousseeuw PJ. Least median of squares regression. J Am Stat Assoc 1984;79:871-80
13. Bland JM, Altman DG. Measuring agreement in method comparison studies. Stat Methods Med Res 1999;8:135-60
14. Marx RG, Menezes A, Horovitz L, et al. A comparison of two time intervals for test-retest reliability of health status instruments. J Clin Epidemiol 2003;56:730-5
15. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10
16. Efron B, Tibshirani RJ. An introduction to the bootstrap. New York: Chapman and Hall, 1993
17. Liang MH, Fossel AH, Larson MG. Comparisons of five health status instruments for orthopedic evaluation. Med Care 1990;28:632-42
18. Streiner DL, Norman GR. Health measurement scales: A practical guide to their development and use. 4th edn. New York: Oxford University Press, 2008
19. Husted JA, Cook RJ, Farewell VT, et al. Methods for assessing responsiveness: A critical review and recommendations. J Clin Epidemiol 2000;53:459-68
20. Kazis LE, Anderson JJ, Meenan RF. Effect sizes for interpreting changes in health status. Med Care 1989;27:S178-89
21. Shapiro DE. The interpretation of diagnostic tests. Stat Methods Med Res 1999;8:113-34
22. Wells GA, Boers M, Shea B, et al. Minimal disease activity for rheumatoid arthritis: A preliminary definition. J Rheumatol 2005;32:2016-24
23. Wells G, Boers M, Tugwell P. Low disease activity state in rheumatoid arthritis: concepts and derivation of minimal disease activity. Clin Exp Rheumatol 2006;24 (Suppl 43):S-52-9
24. Aletaha D, Ward MM, Machold KP, et al. Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states. Arthritis Rheum 2005;52:2625-36
25. Gladman DD, Urowitz MB, Kagal A, et al. Accurately describing changes in disease activity in Systemic Lupus Erythematosus. J Rheumatol 2000;27:377-9
26. Petri M, Genovese M, Engle E, et al. Definition, incidence, and clinical description of flare in systemic lupus erythematosus. A prospective cohort study. Arthritis Rheum 1991;34:937-44
27. Tobon GJ, Saraux A, Gottenberg JE, et al. Role of Fms-like tyrosine kinase 3 ligand as a potential biologic marker of lymphoma in primary Sjogren's syndrome. Arthritis Rheum 2013;65:3218-27
28. Pertovaara M, Korpela M. Serum beta2 microglobulin correlates with the new ESSDAI in patients with Sjogren's syndrome. Ann Rheum Dis 2011;70:2236-7
29. Quartuccio L, Salvin S, Fabris M, et al. BLyS upregulation in Sjogren's syndrome associated with lymphoproliferative disorders, higher ESSDAI score and B-cell clonal expansion in the salivary glands. Rheumatology (Oxford) 2013;52:276-81
30. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61:1143-51
31. Manzi S, Sanchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71:1833-8
32. Stohl W, Hiepe F, Latinis KM, et al. Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus. Arthritis Rheum 2012;64:2328-37
33. Jonsdottir T, Gunnarsson I, Risselada A, et al. Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4
34. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918-30